Smart Contracts Posts and Topic on Reddit

<p>A dataset including two CSVs collecting Reddit posts including respectively:<br>- Permalink: The post's link<br>- Title: The post's title<br>- author: The author's name.<br>- authorUrl: The URL to the author's profile<br>- commentCount: The number of comments related to the post<br>- id: The id of the post<br>-createdDate: The creation date of the reddit post<br>- query: Contains the URL of the board<br>- category: The category related to the subreddit post<br>- score: post score<br>- awardCount: number of awards<br>- silverCount: number of silver gildings<br>- goldCount: number of gold gildings<br>- platinumCount: number of platinum gildings<br>- upvoteRatio: the upvote ratio</p&gt

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)

Introduction: Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence is still very limited. Method: This multicenter retrospective study included patients affected by plaque psoriasis treated with bimekizumab from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients affected by moderate-to-severe plaque psoriasis eligible for systemic treatments were included. The effectiveness of bimekizumab was evaluated in terms of reduction in psoriasis area and severity index (PASI) compared with baseline at weeks 4 and 16. The main outcomes were the percentages of patients achieving an improvement of at least 75% (PASI75), 90% (PASI90) and 100% (PASI100) in PASI score. Results: The study included 237 patients who received at least one injection of bimekizumab. One hundred and seventy-one patients and 114 reached four and 16 weeks of follow-up, respectively. Complete skin clearance was achieved by 43.3% and 75.4% of patients at weeks 4 and 16, respectively. At week 16, 86.8% of patients reported no impact on their quality of life. At week 16, there were no significant differences between bio-naïve and bio-experienced patients in terms of PASI75, PASI90 and PASI100. The most commonly reported adverse events (AEs) were oral candidiasis (10.1%). No severe AEs or AEs leading to discontinuation were observed throughout the study. Conclusion: Our experience supports the effectiveness and tolerability of bimekizumab in a real-world setting with similar results compared with phase-III clinical trials

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)

introduction: genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. while new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. objectives: we aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. methods: bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. the effectiveness of bimekizumab was evaluated in terms of improvement in static physician's global assessment of genitalia (sPGA-G) and psoriasis area and severity Index. results: sixty-five adult patients were enrolled. remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean dermatology life quality Index (DLQI), signifying enhanced quality of life. notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. conclusions: our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results